This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| IMAGEN | |
|---|---|
| Name | IMAGEN |
| Type | longitudinal neuroimaging study |
| Start | 2007 |
| Founders | Jean-Luc Martinot; Gunter Schumann |
| Locations | Cambridge; London; Paris; Munich; Dublin; Madrid; Mannheim; Bilbao |
| Participants | adolescents (initial n ~2,000) |
| Fields | neuroimaging; genetics; psychiatry; psychology |
IMAGEN
IMAGEN is a European longitudinal neuroimaging consortium investigating adolescent brain development, substance use, and mental health. It combines structural and functional neuroimaging with genomics, psychometrics, and environmental assessments to map neurobiological trajectories associated with risk and resilience for psychiatric disorders. The project recruited adolescents across multiple sites and integrates data from cognitive tasks, clinical interviews, and biomarker assays.
The project synthesizes multimodal data—magnetic resonance imaging, genome-wide association arrays, and behavioral phenotyping—from cohorts enrolled in sites including University of Cambridge, King's College London, Institut national de la santé et de la recherche médicale, Ludwig Maximilian University of Munich, Trinity College Dublin, Universidad Autónoma de Madrid, University of Heidelberg, and University of the Basque Country. It aims to identify neurodevelopmental markers that predict trajectories linked to substance use disorders, depression, and externalizing psychopathology, leveraging frameworks common to studies like Adolescent Brain Cognitive Development Study, ENIGMA Consortium, and UK Biobank. IMAGEN’s design emphasizes harmonization across scanners, tasks, and assessment batteries to support transnational comparisons.
Conceived in the mid-2000s by investigators including Jean-Luc Martinot and Gunter Schumann, the consortium began recruitment around 2007 with adolescents aged approximately 14 and established follow-up waves at ages ~16, ~19, and later young adulthood. Its evolution paralleled methodological advances seen in projects led by figures such as Michael Meaney and initiatives like the Human Connectome Project. Funding and governance involved national research councils and European frameworks reminiscent of programs supported by European Research Council and Wellcome Trust. Over time IMAGEN expanded analytic pipelines, incorporated polygenic risk scoring approaches popularized by consortia such as Psychiatric Genomics Consortium, and adopted open-science practices similar to OpenNeuro and DataSHIELD collaborations.
IMAGEN employed multimodal magnetic resonance imaging protocols including structural T1-weighted scanning, diffusion tensor imaging, and task-based functional MRI paradigms adapted from paradigms used in Monica Luciana-style reward tasks and the Montreal Imaging Stress Task lineage. Cognitive and clinical phenotyping utilized instruments with provenance in studies by David Clark and Michael Rutter, while substance use assessments referenced standards from researchers like George Koob. Genotyping used arrays and imputation pipelines comparable to those developed by Wellcome Trust Case Control Consortium, with downstream analyses using tools from PLINK and statistical frameworks articulated by Bradley Efron and Nicholas Fisher. Longitudinal modeling applied mixed-effects approaches advanced by researchers in Biostatistics centers at institutions such as University College London and University of Oxford.
IMAGEN identified associations between adolescent brain activation patterns in reward-related regions and later escalation of alcohol and drug use, echoing neurobehavioral models discussed by Nora Volkow and Antonio R. Damasio. Structural cortical differences and white matter microstructure predicted vulnerability to depressive symptoms and impulsivity, paralleling findings in cohorts studied by Helen Fisher and Edmund Rolls. Polygenic risk scores for psychiatric conditions derived from Psychiatric Genomics Consortium discoveries moderated brain–behavior relationships, demonstrating gene-by-environment interplay similar to observations from Avshalom Caspi and Terrie Moffitt. Cross-site analyses contributed to reproducibility efforts championed by John Ioannidis and meta-analytic strategies used by the ENIGMA Consortium.
IMAGEN collaborated with European and international partners, enabling linkage with resources like Adolescent Brain Cognitive Development Study databases, harmonization initiatives from ENIGMA Consortium, and genetic meta-analyses coordinated by the Psychiatric Genomics Consortium. Dataset sharing has followed models advocated by Open Science Framework and infrastructure supported by entities such as European Bioinformatics Institute and national biobanks including UK Biobank. IMAGEN-derived data products—neuroimaging preprocessed derivatives, genotype data, and behavioral phenotypes—have been used in secondary analyses by groups at Massachusetts General Hospital, Karolinska Institutet, McGill University, and Yale University.
The consortium navigated ethical frameworks from institutional review boards at partner sites including Addenbrooke's Hospital and Hôpital Pitié-Salpêtrière, adhering to consent models influenced by guidelines from World Medical Association and European data protection norms under General Data Protection Regulation. Governance structures balanced data sharing with participant confidentiality using controlled-access repositories and governance templates similar to those proposed by Global Alliance for Genomics and Health. The project addressed return-of-results dilemmas discussed in literature by Eric Green and consent processes developed in dialogues with stakeholders akin to initiatives by Association of Medical Research Charities.
IMAGEN advanced understanding of neurodevelopmental pathways linking adolescent brain changes to psychiatric risk, informing prevention strategies contemplated by public health agencies such as European Centre for Disease Prevention and Control and clinical frameworks in child and adolescent psychiatry exemplified by guidelines from American Academy of Child and Adolescent Psychiatry. Its methodologies influenced imaging harmonization standards at institutions like National Institute of Mental Health and contributed analytic tools adopted by research groups at Imperial College London and University of Toronto. Findings have been cited in translational discussions involving pharmacological research at National Institute on Drug Abuse and behavioral intervention programs evaluated by Cochrane Collaboration.
Category:Neuroimaging studies